Renaissance Technologies LLC Grows Stake in Immunocore Holdings plc (NASDAQ:IMCR)

Renaissance Technologies LLC increased its position in Immunocore Holdings plc (NASDAQ:IMCR) by 14.5% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 646,920 shares of the company’s stock after purchasing an additional 82,120 shares during the quarter. Renaissance Technologies LLC’s holdings in Immunocore were worth $21,924,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. NEOS Investment Management LLC purchased a new position in shares of Immunocore in the 4th quarter valued at approximately $262,000. Tidal Investments LLC purchased a new position in shares of Immunocore in the 1st quarter valued at approximately $423,000. China Universal Asset Management Co. Ltd. lifted its stake in shares of Immunocore by 69.8% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 6,621 shares of the company’s stock valued at $430,000 after purchasing an additional 2,721 shares during the period. Nan Fung Group Holdings Ltd purchased a new position in shares of Immunocore in the 1st quarter valued at approximately $439,000. Finally, DNB Asset Management AS lifted its stake in shares of Immunocore by 35.0% in the 2nd quarter. DNB Asset Management AS now owns 7,211 shares of the company’s stock valued at $244,000 after purchasing an additional 1,868 shares during the period. Hedge funds and other institutional investors own 84.50% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on the company. HC Wainwright restated a “buy” rating and issued a $100.00 target price on shares of Immunocore in a research note on Tuesday. Needham & Company LLC lowered their target price on Immunocore from $81.00 to $78.00 and set a “buy” rating for the company in a research note on Tuesday. Cantor Fitzgerald restated an “overweight” rating on shares of Immunocore in a research note on Monday, September 9th. Oppenheimer reaffirmed an “outperform” rating and set a $89.00 price objective (up previously from $87.00) on shares of Immunocore in a research report on Friday, August 9th. Finally, JPMorgan Chase & Co. reduced their price objective on Immunocore from $70.00 to $66.00 and set an “overweight” rating for the company in a research report on Wednesday, July 10th. One equities research analyst has rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $80.40.

Immunocore Stock Down 3.0 %

Immunocore stock opened at $33.18 on Friday. The firm has a market cap of $1.66 billion, a price-to-earnings ratio of -27.20 and a beta of 0.73. The stock has a fifty day simple moving average of $36.84 and a two-hundred day simple moving average of $46.50. Immunocore Holdings plc has a 12 month low of $32.37 and a 12 month high of $76.98. The company has a current ratio of 5.17, a quick ratio of 5.15 and a debt-to-equity ratio of 1.31.

Immunocore (NASDAQ:IMCR) last posted its earnings results on Thursday, August 8th. The company reported ($0.23) EPS for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.25. The business had revenue of $75.40 million during the quarter, compared to analyst estimates of $74.58 million. Immunocore had a negative return on equity of 14.68% and a negative net margin of 19.16%. The company’s quarterly revenue was up 26.2% compared to the same quarter last year. During the same quarter last year, the company earned ($0.37) EPS. Equities analysts predict that Immunocore Holdings plc will post -1.79 EPS for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.